KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rigel Pharmaceuticals (RIGL) Operating Expenses (2016 - 2025)

Rigel Pharmaceuticals has reported Operating Expenses over the past 16 years, most recently at $46.6 million for Q4 2025.

  • Quarterly results put Operating Expenses at $46.6 million for Q4 2025, up 13.9% from a year ago — trailing twelve months through Dec 2025 was $168.8 million (up 8.85% YoY), and the annual figure for FY2025 was $168.8 million, up 8.85%.
  • Operating Expenses for Q4 2025 was $46.6 million at Rigel Pharmaceuticals, up from $41.0 million in the prior quarter.
  • Over the last five years, Operating Expenses for RIGL hit a ceiling of $49.2 million in Q4 2022 and a floor of $32.2 million in Q2 2023.
  • Median Operating Expenses over the past 5 years was $40.7 million (2022), compared with a mean of $39.9 million.
  • Biggest five-year swings in Operating Expenses: grew 28.47% in 2021 and later tumbled 31.25% in 2023.
  • Rigel Pharmaceuticals' Operating Expenses stood at $41.8 million in 2021, then rose by 17.62% to $49.2 million in 2022, then tumbled by 31.25% to $33.8 million in 2023, then rose by 21.03% to $40.9 million in 2024, then increased by 13.9% to $46.6 million in 2025.
  • The last three reported values for Operating Expenses were $46.6 million (Q4 2025), $41.0 million (Q3 2025), and $40.6 million (Q2 2025) per Business Quant data.